Cellebrite DI Ltd. $CLBT Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 107.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 1,333,563 shares of the company’s stock after buying an additional 689,367 shares during the quarter. Bank of New York Mellon Corp’s holdings in Cellebrite DI were worth $18,376,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Cellebrite DI by 16.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock worth $3,362,000 after buying an additional 24,881 shares during the period. Geode Capital Management LLC lifted its position in shares of Cellebrite DI by 16.2% during the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock worth $5,029,000 after purchasing an additional 43,898 shares during the last quarter. Invesco Ltd. boosted its position in shares of Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after acquiring an additional 209,473 shares in the last quarter. First Trust Advisors LP acquired a new position in Cellebrite DI in the second quarter valued at approximately $341,000. Finally, Marshall Wace LLP purchased a new position in shares of Cellebrite DI in the 2nd quarter valued at $4,472,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Stock Performance

Shares of CLBT opened at $15.07 on Thursday. The stock has a market capitalization of $3.76 billion, a P/E ratio of 53.82, a P/E/G ratio of 1.84 and a beta of 1.17. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98. The company’s fifty day moving average is $14.27 and its two-hundred day moving average is $14.20.

Insider Activity

In other news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the sale, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas E. Hogan sold 103,188 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the transaction, the chief executive officer owned 590,777 shares in the company, valued at approximately $9,310,645.52. This trade represents a 14.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 158,191 shares of company stock valued at $2,479,438 over the last quarter. Corporate insiders own 5.70% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on CLBT. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Needham & Company LLC lowered their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, DA Davidson began coverage on Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.40.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.